Literature DB >> 2995830

Identification of talin as a major cytoplasmic protein implicated in platelet activation.

T O'Halloran, M C Beckerle, K Burridge.   

Abstract

During platelet activation there is a major reorganization in the platelet cytoskeleton that accompanies a rapid change in platelet shape. Many of the events associated with activation are attributed to a rise in calcium concentration within the platelet cytoplasm. One direct consequence of the elevated calcium is the activation of a calcium-dependent protease that cleaves a major platelet protein of relative molecular mass (Mr) approximately 235,000 (235K) to 200K. This protein, P235, has been purified and reported to interact with actin, but the significance of the proteolytic cleavage is unknown. Talin, a cytoskeletal protein in smooth muscle and fibroblasts, binds vinculin and, together with vinculin, is localized in fibroblasts at sites of actin-membrane attachment. Talin and P235 have similar purification procedures, sedimentation coefficients and Stokes' radii (ref. 6 and Molony et al., unpublished observations). Of particular significance, talin is readily cleaved by proteases from approximately 215K to a fragment of approximately 190K. Given these similarities we have investigated the possible relationship between these proteins. Here we demonstrate that platelet P235 is recognized by anti-talin antibody and that it binds vinculin. Both proteins are cleaved in vitro by the calcium-activated protease to yield similar fragments. We conclude that P235 corresponds to the platelet form of talin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995830     DOI: 10.1038/317449a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  25 in total

1.  Age-related and site-specific adaptation of the arterial endothelial cytoskeleton during atherogenesis.

Authors:  J C Yost; I M Herman
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

2.  Calpain I remains intact and intracellular during platelet activation. Immunochemical measurements with monoclonal and polyclonal antibodies.

Authors:  J A Samis; G Zboril; J S Elce
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

3.  Phosphorylation and proteolytic modification of specific cytoskeletal proteins in human neutrophils stimulated by phorbol 12-myristate 13-acetate.

Authors:  S Pontremoli; E Melloni; M Michetti; B Sparatore; F Salamino; O Sacco; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

4.  Integrin-bound talin head inhibits actin filament barbed-end elongation.

Authors:  Corina Ciobanasu; Hong Wang; Véronique Henriot; Cécile Mathieu; Annabelle Fente; Sandrine Csillag; Clémence Vigouroux; Bruno Faivre; Christophe Le Clainche
Journal:  J Biol Chem       Date:  2017-12-24       Impact factor: 5.157

5.  Decreased adhesion of oxidized LDL-stimulated platelets caused by cytochalasin D.

Authors:  B Zhao; T J Filler; C H Rickert; R Dierichs
Journal:  Cell Tissue Res       Date:  1995-04       Impact factor: 5.249

6.  Cytoskeletal domains in the activated platelet.

Authors:  E L Bearer
Journal:  Cell Motil Cytoskeleton       Date:  1995

7.  The adhesion plaque protein, talin, is phosphorylated in vivo in chicken embryo fibroblasts exposed to a tumor-promoting phorbol ester.

Authors:  M C Beckerle
Journal:  Cell Regul       Date:  1990-01

8.  Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera.

Authors:  T Gordon; B Grove; J C Loftus; T O'Toole; R McMillan; J Lindstrom; M H Ginsberg
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Reovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inhibitors.

Authors:  R L Debiasi; M K Squier; B Pike; M Wynes; T S Dermody; J J Cohen; K L Tyler
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Protease and cyclooxygenase inhibitors synergistically prevent activation of human platelets.

Authors:  M Ruggiero; E G Lapetina
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.